company background image
6118 logo

Austar Lifesciences SEHK:6118 Stock Report

Last Price

HK$1.24

Market Cap

HK$635.6m

7D

-16.2%

1Y

-36.1%

Updated

27 Mar, 2024

Data

Company Financials

Austar Lifesciences Limited

SEHK:6118 Stock Report

Market Cap: HK$635.6m

6118 Stock Overview

Austar Lifesciences Limited, an investment holding company, engages in the provision of integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally.

6118 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Austar Lifesciences Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Austar Lifesciences
Historical stock prices
Current Share PriceHK$1.24
52 Week HighHK$3.18
52 Week LowHK$1.16
Beta1.07
1 Month Change-26.19%
3 Month Change-22.98%
1 Year Change-36.08%
3 Year Change-76.20%
5 Year Change-82.34%
Change since IPO-65.27%

Recent News & Updates

Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump

Feb 12
Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump

Market Cool On Austar Lifesciences Limited's (HKG:6118) Revenues

Dec 22
Market Cool On Austar Lifesciences Limited's (HKG:6118) Revenues

Recent updates

Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump

Feb 12
Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump

Market Cool On Austar Lifesciences Limited's (HKG:6118) Revenues

Dec 22
Market Cool On Austar Lifesciences Limited's (HKG:6118) Revenues

We Think Austar Lifesciences (HKG:6118) Has A Fair Chunk Of Debt

Sep 28
We Think Austar Lifesciences (HKG:6118) Has A Fair Chunk Of Debt

Here's Why Austar Lifesciences (HKG:6118) Has A Meaningful Debt Burden

Mar 31
Here's Why Austar Lifesciences (HKG:6118) Has A Meaningful Debt Burden

Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Sep 19
Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Is Austar Lifesciences (HKG:6118) A Risky Investment?

Apr 06
Is Austar Lifesciences (HKG:6118) A Risky Investment?

Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet

Oct 24
Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet

With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting

Sep 27
With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting

If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late

May 31
If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Mar 31
Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?

Mar 01
Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?

Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Feb 01
Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?

Jan 11
Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Dec 21
Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Can You Imagine How Jubilant Austar Lifesciences' (HKG:6118) Shareholders Feel About Its 191% Share Price Gain?

Dec 07
Can You Imagine How Jubilant Austar Lifesciences' (HKG:6118) Shareholders Feel About Its 191% Share Price Gain?

Here's What Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Structure Looks Like

Nov 23
Here's What Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Structure Looks Like

Shareholder Returns

6118HK Life SciencesHK Market
7D-16.2%-3.5%0.3%
1Y-36.1%-63.0%-12.7%

Return vs Industry: 6118 exceeded the Hong Kong Life Sciences industry which returned -63% over the past year.

Return vs Market: 6118 underperformed the Hong Kong Market which returned -12.7% over the past year.

Price Volatility

Is 6118's price volatile compared to industry and market?
6118 volatility
6118 Average Weekly Movement13.7%
Life Sciences Industry Average Movement11.4%
Market Average Movement7.3%
10% most volatile stocks in HK Market14.7%
10% least volatile stocks in HK Market3.7%

Stable Share Price: 6118's share price has been volatile over the past 3 months.

Volatility Over Time: 6118's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.

About the Company

FoundedEmployeesCEOWebsite
19911,838Mars Hohttps://www.austar.com.hk

Austar Lifesciences Limited, an investment holding company, engages in the provision of integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. It operates through six segments: Liquid and Bioprocess System; Clean Room and Automation Control and Monitoring System; Powder and Solid System; GMP Compliance Service; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment. The company offers liquid and bioprocess systems, including pharmaceutical water, and liquid preparation and bioprocess systems; clean room enclosure, automation control and monitoring systems; and freeze-dryer, sterile filling, and visual inspection equipment, as well as clean utility, powder, and solid equipment and systems.

Austar Lifesciences Limited Fundamentals Summary

How do Austar Lifesciences's earnings and revenue compare to its market cap?
6118 fundamental statistics
Market capHK$635.60m
Earnings (TTM)-HK$35.30m
Revenue (TTM)HK$1.91b

0.3x

P/S Ratio

-18.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6118 income statement (TTM)
RevenueCN¥1.76b
Cost of RevenueCN¥1.43b
Gross ProfitCN¥336.05m
Other ExpensesCN¥368.66m
Earnings-CN¥32.61m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.064
Gross Margin19.05%
Net Profit Margin-1.85%
Debt/Equity Ratio55.5%

How did 6118 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.